Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis-Reference-Cited by-同舟云学术

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis

Published:2024-01-15 Issue:5 Volume:130 Page:808-818
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Le Teuff Gwénaël^ORCID,Cozic Nathalie,Boyer Jean-Christophe,Boige Valérie,Diasio Robert B.,Taieb Julien^ORCID,Meulendijks Didier,Palles Claire^ORCID,Schwab Matthias,Deenen Maarten,Largiadèr Carlo R.^ORCID,Marinaki Anthony,Jennings Barbara A.,Wettergren Yvonne^ORCID,Di Paolo Antonello,Gross Eva,Budai Barna,Ackland Stephen P.,van Kuilenburg André B. P.,McLeod Howard L.^ORCID,Milano Gérard^ORCID,Thomas Fabienne,Loriot Marie-Anne,Kerr David^ORCID,Schellens Jan H. M.,Laurent-Puig Pierre^ORCID,Shi Qian,Pignon Jean-Pierre,Etienne-Grimaldi Marie-Christine,

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-023-02517-2.pdf

Reference52 articles.

1. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for Stage III colon cancer. N. Engl J Med. 2018;378:1177–88.

2. Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist. 2021;26:1008–16.

3. Barin-Le Guellec C, Lafay-Chebassier C, Ingrand I, Tournamille J-F, Boudet A, Lanoue M-C, et al. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France. Eur J Cancer. 2020;124:37–46.

4. van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40:939–50.

5. Pallet N, Hamdane S, Garinet S, Blons H, Zaanan A, Paillaud E, et al. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. Br J Cancer. 2020;123:811–8.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to: “Is uracil enough for effective pre-emptive DPD testing?”;Clinical Chemistry and Laboratory Medicine (CCLM);2024-08-15

2. Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis;Clinical Chemistry and Laboratory Medicine (CCLM);2024-06-19

3. Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy;European Journal of Cancer;2024-06

4. Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities;International Journal of Biological Sciences;2024